Welireg (belzutifan) — Highmark
von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), CNS hemangioblastoma, or pancreatic neuroendocrine tumor (pNET) not requiring immediate surgery
Initial criteria
- age ≥ 18 years
- diagnosis of von Hippel-Lindau (VHL) disease
- diagnosis of one of the following not requiring immediate surgery: renal cell carcinoma, CNS hemangioblastoma, or pancreatic neuroendocrine tumor
Reauthorization criteria
- prescriber attests that the member is tolerating therapy AND has experienced a therapeutic response defined as disease improvement OR delayed disease progression
Approval duration
12 months